Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring

Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring2018-01-17T17:03:31-05:00

Probiotic microorganisms: how they affect intestinal pathophysiology

Probiotic microorganisms: how they affect intestinal pathophysiology2018-01-17T17:03:31-05:00

Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis

Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis2018-01-17T17:03:31-05:00

Effect of early versus delayed interferon beta-1b treatment on disability after a fi rst clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study

Effect of early versus delayed interferon beta-1b treatment on disability after a fi rst clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study2018-01-17T17:03:31-05:00

The Janus face of CNS-directed autoimmune response: a therapeutic challenge

The Janus face of CNS-directed autoimmune response: a therapeutic challenge2018-01-17T17:03:31-05:00

Molecular mimicry in the autoimmune pathogenesis of rheumatic heart disease

Molecular mimicry in the autoimmune pathogenesis of rheumatic heart disease2018-01-17T17:03:31-05:00

Drug researchers leak secrets to Wall St.

Drug researchers leak secrets to Wall St.2018-01-17T17:03:31-05:00

Cell Defenses and the Sunshine Vitamin

Cell Defenses and the Sunshine Vitamin2018-01-17T17:03:31-05:00

Multiple Sclerosis and Epstein-Barr Virus

Multiple Sclerosis and Epstein-Barr Virus2018-01-17T17:03:31-05:00

Temporal Relationship Between Elevation of Epstein-Barr Virus Antibody Titers and Initial Onset of Neurological Symptoms in Multiple Sclerosis

Temporal Relationship Between Elevation of Epstein-Barr Virus Antibody Titers and Initial Onset of Neurological Symptoms in Multiple Sclerosis2018-01-17T17:03:31-05:00